Journal of Diabetology Research
Abstract:
Tirzepatide (Mounjaro), a dual GLP-1 and GIP receptor agonist, has emerged as one of the most promising therapies for metabolic control in patients with obesity and type 2 diabetes mellitus (DM2). This systematic review aimed to evaluate the clinical efficacy and safety of tirzepatide, with a focus on reducing glycated hemoglobin (HbA1c), weight loss and cardiovascular impact. Five randomized clinical trials published between 2020 and 2023 were included. The results showed that tirzepatide promoted HbA1c reductions of between 1.8% and 2.4%, and body weight losses of up to 20.9%, being superior to other incretin-based therapies, such as semaglutide and liraglutide. In addition, three of the five included studies showed a reduction in cardiovascular events, especially in patients with DM2 and high CV risk. Tirzepatide showed a favorable safety profile, with predominantly gastrointestinal adverse effects and a low incidence of hypoglycemia. The weekly dosage and multifactorial effect make this drug an attractive option for integrated metabolic management. However, limitations such as high cost and lack of data in special populations should be considered. It is concluded that tirzepatide represents a relevant therapeutic advance, with the potential to change clinical guidelines in the treatment of obesity and DM2.
Keywords: tirzepatida, GLP-1, GIP, type 2 diabetes, obesity, glycemic control, weight loss, cardiovascular events.
Citation:
Dr. Thiago Augusto Rochetti Bezerra. Use of Tirzepatida (Mounjaro) as a Therapeutic Agent in Obesity and Type 2 Diabetes: A Systematic Review on Metabolic Control with GLP-1 Agonists. Journal of Diabetology Research 2025.
Comments
Post a Comment